Iron induced oxidative damage as a potential factor in age-related macular degeneration: The Cogan lecture

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 11, 2006, Pages 4660-4664

  Dunaief, Joshua L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Stellar Chance Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYOXYQUINOLINE; ARGININE; CARRIER PROTEINS AND BINDING PROTEINS; CERULOPLASMIN; CITRULLINE; DEFEROXAMINE; HEPHAESTIN; IRON; LIPOFUSCIN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; HFE PROTEIN, HUMAN; HFE PROTEIN, MOUSE; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ACERULOPLASMINEMIA; ARTICLE; DISEASE COURSE; DISEASE MODEL; DRUSEN; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RISK FACTOR; ANIMAL; DRUG EFFECT; METABOLISM; RETINA; RETINA MACULA DEGENERATION;

ANIMALS; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON OVERLOAD; MACULAR DEGENERATION; MEMBRANE PROTEINS; OXIDATIVE STRESS; PIGMENT EPITHELIUM OF EYE; RETINA;

EID: 34247143301     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0568     Document Type: Article

References (55)

1. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598-614.
2. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
3. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
4. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
5. Haines JL, Hauser MA, Schmidt S, et al.Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
6. Hageman GS, Anderson DH, Johnson LV, et al.A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227-7232.
7. Perry G, Sayre LM, Atwood CS, et al. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs. 2002;16:339-352.
8. Redmond TM, Poliakov E, Yu S, Tsai JY, Lu Z, Gentleman S. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci USA. 2005;102:13658-13663.
9. Chevion M. A site-specific mechanism for free radical induced biological damage: the essential role of redox-active transition metals. Free Radic Biol Med. 1988;5:27-37.
10. Burdo JR, Connor JR. Brain iron uptake and homeostatic mechanisms: an overview. Biometals 2003;16:63-75.
11. Moos T. Brain iron homeostasis. Dan Med Bull. 2002;49:279-301.
12. Rouault TA. Iron on the brain. Nat Genet. 2001;28:299-300.
13. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr. 1998;67:972S-977S.
14. Doly M, Bonhomme B, Vennat JC. Experimental study of the retinal toxicity of hemoglobinic iron. Ophthalmic Res. 1986;18:21-27.
15. Vergara O, Ogden T, Ryan S. Posterior penetrating injury in the rabbit eye: effect of blood and ferrous ions. Exp Eye Res. 1989;49:1115-1126.
16. Tawara A. Transformation and cytotoxicity of iron in siderosis bulbi. Invest Ophthalmol Vis Sci. 1986;27:226-236.
17. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762-773.
18. Yefimova MG, Jeanny JC, Keller N, et al. Impaired retinal iron homeostasis associated with defective phagocytosis in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci. 2002;43:537-545.
19. Yamaguchi K, Takahashi S, Kawanami T, Kato T, Sasaki H. Retinal degeneration in hereditary ceruloplasmin deficiency. Ophthalmologica. 1998;212:11-14.
20. Albert D, Jakobiec F. Principles and Practice of Ophthalmology. Philadelphia: WB Saunders; 2000.
21. Newell FW, Johnson RO 2nd, Huttenlocher PR. Pigmentary degeneration of the retina in the Hallervorden-Spatz syndrome. Am J Ophthalmol. 1979;88:467-471.
22. Dunaief JL, Richa C, Franks EP, et al. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology. 2005;112:1062-1065.
23. Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch Ophthalmol. 2003;121:1099-1105.
24. Dentchev T, Hahn P, Dunaief JL. Strong labeling for iron and the iron-handling proteins ferritin and ferroportin in the photoreceptor layer in age-related macular degeneration. Arch Ophthalmol. 2005;123:1745-1746.
25. Chowers I, Wong R, Dentchev T, et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47:2135-2140.
26. Li ZL, Lam S, Tso MO. Desferrioxamine ameliorates retinal photic injury in albino rats. Curr Eye Res. 1991;10:133-144.
27. Chen L, Dentchev T, Wong R, et al.Increased expression of ceruloplasmin in the retina following photic injury. Mol Vis. 2003;9:151-158.
28. Wetzel MG, Li J, Alvarez RA, Anderson RE, O'Brien PJ. Metabolism of linolenic acid and docosahexaenoic acid in rat retinas and rod outer segments. Exp Eye Res. 1991;53:437-446.
29. Yefimova MG, Jeanny JC, Guillonneau X, et al.Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest Ophthalmol Vis Sci. 2000;41:2343-2351.
30. Miyajima H, Kono S, Takahashi Y, Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis. 2002;29:433-438.
31. Gitlin JD. Aceruloplasminemia. Pediatr Res. 1998;44:271-276.
32. Hahn P, Qian Y, Dentchev T, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci USA. 2004;101:13850-13855.
33. Klomp LW, Gitlin JD. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet. 1996;5:1989-1996.
34. Osaki S. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin). J Biol Chem. 1966;241:5053-5059.
35. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci. 2002;22:6578- 6586.
36. Davis AA, Hunt RC. Transferrin is made and bound by photoreceptor cells. J Cell Physiol. 1993;156:280-285.
37. Levin LA, Geszvain KM. Expression of ceruloplasmin in the retina: induction after optic nerve crush. Invest Ophthalmol Vis Sci. 1998;39:157-163.
38. Rattner A, Nathans J. The genomic response to retinal disease and injury: evidence for endothelin signaling from photoreceptors to glia. J Neurosci. 2005;25:4540-4549.
39. Miyahara T, Kikuchi T, Akimoto M, Kurokawa T, Shibuki H, Yoshimura N. Gene microarray analysis of experimental glaucomatous retina from cynomolgus monkey. Invest Ophthalmol Vis Sci. 2003;44:4347-4356.
40. Farkas RH, Chowers I, Hackam AS, et al. Increased expression of iron-regulating genes in monkey and human glaucoma. Invest Ophthalmol Vis Sci. 2004;45:1410-1417.
41. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. Expression of acute-phase response proteins in retinal Müller cells in diabetes. Invest Ophthalmol Vis Sci. 2005;46:349-357.
42. McGahan MC, Fleisher LN. Antioxidant activity of aqueous and vitreous humor from the inflamed rabbit eye. Curr Eye Res. 1986;5:641-645.
43. Bacon BR, Schilsky ML. New knowledge of genetic pathogenesis of hemochromatosis and Wilson's disease. Adv Intern Med. 1999;44:91-116.
44. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998;95:1472-1477.
45. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell. 1998;93:111-123.
46. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA. 2001;98:8160-8161.
47. Roth AM, Foos RY. Ocular pathologic changes in primary hemochromatosis. Arch Ophthalmol. 1972;87:507-514.
48. Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem. 2005;13:773-783.
49. Richardson DR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann NY Acad Sci. 2004;1012:326-341.
50. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1984;68:873-877.
51. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181-184.
52. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 1984;91:443-451.
53. Leure-duPree AE, Connor MJ. The effect of deferoxamine, an iron chelator, on the morphology of the retina. Prog Clin Biol Res. 1987;247:517-529.
54. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003;37:899-909.
55. Waugh WH. Iron chelation by dibasic amino acid prevents glycoprotein insolubilities: a strategy to inhibit age-related macular degeneration? J Appl Rese. 2004;4:208-214.